Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Novo Nordisk A/S - Reduction of the share capital

Posted on: 24 Apr 18

Bagsværd, Denmark, 24 April 2018 - At Novo Nordisk's Annual General Meeting on 22 March 2018, it was decided to reduce the company's B share capital from DKK 392,512,800 to DKK 382,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 490,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 382,512,800.

The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
Further information

Anne Margrethe Hauge +45 4442 3450
Ken Inchausti (US) +1 609 786 8316
Peter Hugreffe Ankersen +45 3075 9085
Anders Mikkelsen +45 3079 4461
Christina Kjær +45 3079 3009

Company announcement No 34 / 2018



Last updated on: 24/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.